Duocarmycin TM is primarily utilized in the field of oncology due to its potent antitumor properties. It functions by alkylating DNA, which disrupts the replication process of cancer cells, leading to their destruction. This makes it a valuable component in the development of antibody-drug conjugates (ADCs), where it is linked to monoclonal antibodies that specifically target cancer cells, thereby minimizing damage to healthy tissues. Its high cytotoxicity is leveraged in research to create more effective and targeted cancer therapies, particularly for hard-to-treat malignancies. Additionally, Duocarmycin TM is studied for its potential in enhancing the efficacy of existing chemotherapy regimens, offering hope for improved outcomes in cancer treatment.